Jazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference
JAZZDUBLIN, Nov. 18, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in Citi's 2025 Global Healthcare Conference. Company management will participate in a fireside chat on Tuesday, December 2, 2025, at 6:45 a.m. PST / 9:45 a.m....
Jazz Pharmaceuticals to Participate in the 2025 Wells Fargo Healthcare Conference
JAZZDUBLIN, Aug. 21, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the 2025 Wells Fargo Healthcare Conference. Company management will participate in a fireside chat on Wednesday, September 3, 2025, at 6:30 a.m. PDT / 9:30...
Jazz Pharmaceuticals to Host Modeyso™ (dordaviprone) Investor Webcast on August 27, 2025
JAZZDUBLIN, Aug. 20, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will host an investor webcast on Wednesday, August 27, 2025, at 4:30 p.m. EDT / 9:30 p.m. IST to provide an overview of clinical data, patient need and commercialization strategy for Modeyso™ (dordaviprone)....
Needham Reiterates Buy on Jazz Pharmaceuticals, Maintains $202 Price Target
JAZZFDA Accepts Jazz Pharma's sNDA For Zepzelca In Combination With Atezolizumab As First-Line Maintenance Treatment For People With ES-SCLC For Priority Review, With PDUFA Action Date Of October 7, 2025
JAZZJazz Pharmaceuticals Reveals Phase 4 Data Evaluating Treatment Benefits Of Xywav Oral Solution In People With Narcolepsy At SLEEP 2025
JAZZJazz Pharma's Zepzelca Combo Shows Survival Edge In Lung Cancer Study
JAZZJazz Pharma's Zepzelca plus Tecentriq significantly improved survival in a Phase 3 study for extensive-stage small-cell lung cancer patients.
The Analyst Verdict: Jazz Pharmaceuticals In The Eyes Of 11 Experts
JAZZNeedham Reiterates Buy on Jazz Pharmaceuticals, Maintains $202 Price Target
JAZZJazz Pharmaceuticals Announces Phase 3 IMforte Trial Results Showing Zepzelca Plus Atezolizumab First-Line Maintenance Therapy Reduces Disease Progression Risk By 46% And Extends Median Overall Survival To 13.2 Months In ES-SCLC; Data Presented At ASCO 20
JAZZJazz Pharmaceuticals Reports Long-Term Phase 2 Data For Ziihera Showing 36.5-Month Median Overall Survival And Durable Responses In HER2-Positive Gastroesophageal Cancer, With Manageable Safety Profile; Results Presented At ASCO 2025 And Published In The
JAZZBaird Maintains Outperform on Jazz Pharmaceuticals, Lowers Price Target to $155
JAZZRBC Capital Maintains Outperform on Jazz Pharmaceuticals, Lowers Price Target to $172
JAZZPiper Sandler Reiterates Overweight on Jazz Pharmaceuticals, Lowers Price Target to $147
JAZZMorgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Lowers Price Target to $166
JAZZNeedham Reiterates Buy on Jazz Pharmaceuticals, Maintains $200 Price Target
JAZZJazz Pharmaceuticals Lowers FY2025 Adj EPS Guidance from $22.50-$24.00 to $4.00-$5.60 vs $23.25 Est; Affirms FY2025 Sales Guidance of $4.15B-$4.40B vs $4.29B Est
JAZZJazz Pharmaceuticals Q1 Adj. EPS $1.68 Misses $4.66 Estimate, Sales $897.84M Miss $985.39M Estimate
JAZZPreview: Jazz Pharmaceuticals's Earnings
JAZZJazz Pharma Secures CHMP Support for Zanidatamab for Treatment of Advanced HER2-Positive Biliary Tract Cancer
JAZZWhere Jazz Pharmaceuticals Stands With Analysts
JAZZNeedham Reiterates Buy on Jazz Pharmaceuticals, Maintains $210 Price Target
JAZZJazz Pharmaceuticals Enters Preliminary $145M Class Settlement Agreement To Resolve Antitrust And Consumer Protection Claims Related To Patent Litigation Settlements For Xyrem, Expected To Record Pre-Tax Charge In Q1 2025
JAZZHC Wainwright & Co. Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $217
JAZZMorgan Stanley Assumes Jazz Pharmaceuticals at Overweight, Raises Price Target to $183
JAZZUBS Upgrades Jazz Pharmaceuticals to Buy, Raises Price Target to $179
JAZZTruist Securities Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $230
JAZZA Glimpse Into The Expert Outlook On Jazz Pharmaceuticals Through 12 Analysts
JAZZNeedham Reiterates Buy on Jazz Pharmaceuticals, Maintains $210 Price Target
JAZZBarclays Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $200
JAZZCantor Fitzgerald Downgrades Jazz Pharmaceuticals to Neutral, Raises Price Target to $150
JAZZWatching Jazz Pharmaceuticals; Shares See Volume To The Downside After Cantor Issues Note; Downgraded The Stock To Neutral
JAZZPiper Sandler Reiterates Overweight on Jazz Pharmaceuticals, Raises Price Target to $176
JAZZRBC Capital Maintains Outperform on Jazz Pharmaceuticals, Lowers Price Target to $178
JAZZJP Morgan Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $209
JAZZNeedham Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $210
JAZZJazz Pharmaceuticals Sees 2024 Total Revenues $4.15B-$4.4B vs $4.325B Est.
JAZZJazz Pharmaceuticals Q4 2024 Adj. EPS $6.60 Beats $5.81 Estimate, Sales $1.088B Beat $1.060B Estimate
JAZZDeep Dive Into Jazz Pharmaceuticals Stock: Analyst Perspectives (9 Ratings)
JAZZWells Fargo Upgrades Jazz Pharmaceuticals to Overweight, Raises Price Target to $170
JAZZBaird Maintains Outperform on Jazz Pharmaceuticals, Raises Price Target to $162
JAZZJazz Pharmaceuticals Reports Strong Q3: Will Debt Weigh On Its Future Growth?
JAZZCEO Bruce Cozadd emphasized that Jazz remains "confident in its revenue guidance of $4.0 to $4.1 billion" for the full year.
Jazz Pharmaceuticals Sees FY24 Adj EPS $19.50-$20.60 Vs $19.59 Est.
JAZZJazz Pharmaceuticals Q3 2024 Adj EPS $6.61 Beats $5.50 Estimate, Sales $1.05B Beat $1.04B Estimate
JAZZJazz Pharmaceuticals Presents New Data At Psych Congress 2024 Confirming Xywav Oral Solution Treatment Benefits In Narcolepsy And Idiopathic Hypersomnia
JAZZJazz Pharmaceuticals And Life Science Cares Collaborate For Social Impact Through Employee Volunteerism
JAZZJazz Pharmaceuticals And Sumitomo Pharma Announce Exclusive License Agreement To Develop And Commercialize DSP-0187; Sumitomo Pharma To Receive $50M Upfront Payment
JAZZJazz Pharma Raises FY22 Sales Guidance From $3.46B-$3.66B To $3.5B-$3.7B vs $3.58B Estimate, Adj. EPS From $16-$17 To $16.70-$17.7 vs $16.54 Estimate
JAZZJazz Pharmaceuticals Q1 Adj. EPS $3.73 Misses $3.83 Estimate, Sales $813.72M Miss $853.52M Estimate
JAZZ